NCT06294925 (EFFECT-UC) is a clinical trial of Etrasimod in Colitis, Ulcerative, sponsored by Pfizer.

Who is sponsoring NCT06294925?

NCT06294925 is sponsored by Pfizer.

What drugs are being tested in NCT06294925?

Interventions in NCT06294925: Etrasimod.

What condition does NCT06294925 study?

NCT06294925 studies Colitis, Ulcerative.

Is NCT06294925 still recruiting?

NCT06294925 is currently recruiting now. Last updated 30 March 2026.

Last reviewed 2026-03-30 · How we verify

NCT06294925: EFFECT-UC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative Colitis

Recruiting now Last updated 30 March 2026

What this trial tests

trial testing Etrasimod in Colitis, Ulcerative in 360 participants. Currently enrolling.

Timeline

8 May 2024

Primary endpoint
30 June 2026

30 June 2026

Quick facts

Lead sponsor	Pfizer
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	360
Start date	8 May 2024
Primary completion	30 June 2026
Estimated completion	30 June 2026
Sites	34 locations across Germany, United Kingdom, Canada

Drugs / interventions tested

Etrasimod (ETRASIMOD) — full drug profile →

Conditions studied

Colitis, Ulcerative — all drugs for Colitis, Ulcerative →

Sponsor

Pfizer — full company profile →

Who can join

Adults 18 to 64, any sex, with Colitis, Ulcerative. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this real world non-interventional study is to learn about the effects of etrasimod as treatment for patients with moderate to severe ulcerative colitis. Patients will be treated according to standard of care and will only be included in the study if etrasimod is the best treatment choice according to the treating physician. Additionally, patients have to be between 18 and 65 years of age and should not have taken etrasimod in the past. All patients will be prescribed etrasimod according to standard of care. Assessments will be conducted according to standard of care with the exception of health questionnaires which will be completed by the patients online on their own device. The study duration is 52 weeks with 28 days of safety follow-up. Patients will visit their treating physician as they would if they were not enrolled in the study. During the study duration, patients will be asked to complete health questionnaires on a regular basis either on their mobile phone, tablet or computer. The effects of etrasimod will be analyzed for each patient comparing to their disease activity prior to the start of etrasimod.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting the Sphingosine-1-Phosphate Pathway: New Opportunities in Inflammatory Bowel Disease Management.
Kitsou K, Kokkotis G, Rivera-Nieves J, Bamias G. · · 2024 · cited 22× · PMID 39322927 · DOI 10.1007/s40265-024-02094-5
The Current Sphingosine 1 Phosphate Receptor Modulators in the Management of Ulcerative Colitis.
Choon XY, Yeo JH, White C, Sharma E, et al · · 2025 · cited 3× · PMID 40429469 · DOI 10.3390/jcm14103475
Effectiveness of etrasimod on disease activity and patient-reported outcomes in ulcerative colitis-EFFECT-UC: a non-interventional, multinational, prospective cohort study protocol.
Moran GW, Radford SJ, Walsh A, Battat R, et al · · 2025 · PMID 41448713 · DOI 10.1136/bmjopen-2025-106141

Verify or expand the search:

Other trials of Etrasimod

Trials testing the same drug.

NCT07470879 — A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis · Phase 2 · not yet recruiting
NCT07153159 — A Study to Learn How the Study Medicine Called Etrasimod is Taken up Into Blood and Breastmilk of Healthy Breastfeeding · Phase 1 · recruiting
NCT06398626 — An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis · recruiting
NCT05287126 — A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis · Phase 2 · recruiting
NCT05061446 — Etrasimod Dose-Ranging Versus Placebo as Induction Therapy Study in Adult Japanese Subjects With Moderately to Severely · Phase 2 · completed

Other recruiting trials for Colitis, Ulcerative

Currently open trials in the same condition.

NCT07302360 — A Real-World Study of Guselkumab in Chinese Participants With Ulcerative Colitis · recruiting
NCT07242248 — A Study to Observe Real-world Evidence of Guselkumab Treatment in Participants With Ulcerative Colitis and Crohn's Disea · recruiting
NCT07196748 — A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Col · Phase 3 · recruiting
NCT07102368 — A Study to Generate Real-world Evidence of Guselkumab Effectiveness in Inflammatory Bowel Disease in Germany · recruiting
NCT06651281 — Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Coli · Phase 3 · recruiting

Other Pfizer trials

Trials by the same sponsor.

NCT04982848 — Korea Post Marketing Surveillance (PMS) Study of Talzenna® · not yet recruiting
NCT06873191 — A Study to Learn More About Tukysa Once it is Out in the Korean Market · not yet recruiting
NCT07497854 — A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea · not yet recruiting
NCT06507904 — A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Anta · Phase 1 · not yet recruiting
NCT06864585 — A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06294925 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pfizer
Last refreshed: 30 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06294925.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing